ClinicalTrials.gg
RecruitingNCT07491458AMPLIFYUpdated May 18, 2026

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 2 interventional study of HU6 and Placebo in MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Rivus Pharmaceuticals, Inc.. Recruiting at 31 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Rivus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
26th of 162
180 · median 45
Started
2026
with 13 others
Phase 2
43 of 211
5 open now
Primary completion
2027-02
later than 13 of 46 live
Registered
199th of 211
by date

Among the 211 studies in Fatty Liver with a site in United States, this one is the 26th largest by planned enrollment of the 162 interventional ones that give a count, is one of 14 that started in 2026, is one of 43 in phase 2, reaches primary completion later than 13 of the 46 other live ones, and was the 199th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.

Read the detailed description

This is a 2-part randomized, double-blind, placebo-controlled, multicenter trial with an open label extension (OLE) to evaluate the safety and exposure of HU6 as well as the effect of HU6 on liver fat and other symptoms associated with MASH.

The 2-part trial design consists of a blinded intervention period and, for participants who completed the blinded intervention period, an option to continue in an OLE intervention period. The blinded trial design consists of a screening period, a blinded intervention period, an end of treatment (EOT)/early termination (ET) visit, a safety follow-up visit, and two long-term follow up visits.

03

Conditions studied

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female ≥30 years of age at time of signing the .
  • Diagnosed with metabolic dysfunction-associated steatohepatitis (MASH)
  • Women of must not be pregnant or breastfeeding and must use and agree to continue to use a highly effective method throughout time on study.
  • (BMI) ≥27.0 kg/m2 to ≤44 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Have acute or chronic hepatitis, signs, and symptoms of any other liver disease (eg, Wilson's disease) other than MASH
  • Cholecystectomy or any other surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment.
  • History (including any family history) of malignant hyperthermia.
  • History of within 5 years (except cutaneous basal or squamous cell carcinoma, carcinoma-in-situ, or low-grade prostate cancer).
  • History of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.
  • Significant and unstable lung disease ( [COPD], emphysema, pulmonary fibrosis, or asthma) requiring oxygen or chronic daily medication. Note that mild, stable COPD and asthma on inhalers are allowed.
  • Monogenetic diabetes or type 1 diabetes.
  • History of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to Screening.
  • History of agranulocytosis.
  • History of or active evidence of ophthalmological conditions
  • Untreated, uncontrolled, or unstable hypertension
  • Use of any of the following medications/therapies: Vitamin E: use of ursodiol or high-dose vitamin E (>400 IU/day) for a duration of >1 month within 6 months or started high dose vitamin E for any duration within 3 months prior to screening
  • Within 3 months prior to screening or plan to use prior to coming off study drug: resmetirom (Rezdiffra®), GLP 1 agonists and gastric inhibitory polypeptide (GIP)/GLP-1 agonists, Weight loss medications/therapies including: herbal preparation, over the counter (OTC) drug, mail order or prescription drug, Oral antidiabetic medications/therapies including: insulin, meglitinides, thiazolidinediones. Prescription or OTC stimulants. Recent or current use of obeticholic acid (Ocaliva®), systemic , methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines. Warfarin, heparin, factor Xa inhibitors due to risk of bleeding, Medications with high risk of idiosyncratic drug-induced neutropenia (IDIN) or agranulocytosis.
  • History of hepatitis or (HIV1 \& HIV2)
  • Intolerance to MRI or with conditions for MRI procedures
  • Participation in another clinical trial at the time of screening or exposure to any product, including topical agents, within 28 days prior to starting study treatment
  • Additional inclusion/exclusion criteria could apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HU6 450 mg

    450 mg Once Daily (QD)

    Drug: HU6

  • Experimental
    HU6 300 mg

    300 mg Twice Daily (BID)

    Drug: HU6

  • Placebo comparator
    Placebo Once Daily

    Placebo Once Daily (QD)

    Other: Placebo

  • Placebo comparator
    Placebo Twice Daily

    Placebo Twice Daily (BID)

    Other: Placebo

Interventions

  • DrugHU6

    Drug pages: HU6 · Dinifedriton

    HU6 is being evaluated for efficacy in MASH

  • OtherPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Adverse Events (AEs)

    Time frame: 26 weeks

  2. Percent change from baseline to Week 26 In Liver Fat Assessed by MRI-PDFF

    Time frame: 26 weeks

  3. Percentage of participants with Liver Fat reduction by ≥30% Assessed by MRI-PDFF

    Time frame: 26 weeks

  4. Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: 26 weeks

  5. Trough Plasma Concentration (Ctrough)

    Time frame: 26 weeks

  6. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 26 weeks

  7. Time to Maximum Plasma Concentration (Tmax)

    Time frame: 26 weeks

  8. Plasma Clearance of drug after extravascular administration (CL/F)

    Time frame: 26 weeks

  9. Volume of distribution after extravascular administration (V/F)

    Time frame: 26 weeks

  10. Drug elimination half-life (t½)

    Time frame: 26 weeks

07

Study locations

31 of 31 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 24, 2026
StartActual
Feb 13, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2028
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07491458
Lead sponsor
Rivus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Feb 13, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
May 18, 2026

Study contacts

Clinical Operations Lead
Contact
jsoto@rivuspharma.com
6173887757
VP, Clinical Operations
Contact
jdurden@rivuspharma.com
8435683621
Stefanie Mason, MD
study director · Rivus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HU6 · Dinifedriton

Start the discussion